Biotech Values

[tony111]

Lorcaserin has minimal side effects. The drug was studied up to two year and enrolled the most patients compared to Qnexa and Contrave's one year studies. The cardiovascular effect and abuse potential of Lorcaserin was thoroughly studied. All the analysts agree Lorcaserin is approvable based on safety, but argues the poor efficacy cannot compete with Qnexa. If Qnexa gets a thumb down due to safety, Lorcaserin basically has the whole pie.